Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rubis says any bid talks at 'very preliminary' stage

(Sharecast News) - French fuel distributor Rubis said talks with potential bidders were "very preliminary" a day after reports that private equity firm CVC Capital Partners and commodities trader Trafigura were separately considering bids for the company. In a short statement, Rubis said that it had been in contact with "various industrial and financial counterparties" and "maintained a dialogue with all relevant stakeholders".

"Rubis is committed to exploring and considering the potential options that could arise for the group in the context of discussions that, to date, remain very preliminary," it added.

The company, which distributes petroleum products such as gasoline and bitumen across Europe, Africa and the Caribbean, currently has a market value of around €3bn.

Investor speculation over Rubis's future had recently intensified amid mounting pressure to overhaul its governance.

The company operates as a société en commandite par actions, a partnership limited by shares that gives its founders broad influence despite holding just over 2% of the equity.

Founders Gilles Gobin and Jacques Riou said they would step down from the management board in 2027, while activist shareholders Patrick Molis and Ronald Sämann had pushed for reforms and for a shift away from solar investments.

Bolloré Group and Molis had also increased their stakes in recent months.

Adding to the momentum, Bernstein initiated coverage of Rubis on Monday with an 'outperform' rating and a €38.70 price target, describing the company as an "anti-fragile jewel" with a 25-year record of dividend growth and a current yield of 4.5%.

Reporting by Frank Prenesti and Josh White for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.